Experimental drug targets smallpox and monkeypox after exposure

NCT ID NCT02080767

AVAILABLE Disease control Sponsor: U.S. Army Medical Research and Development Command Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial tests the drug tecovirimat in people who have been exposed to or infected with orthopox viruses, including smallpox, monkeypox, and cowpox. Participants receive oral tecovirimat to see if it can control the infection and prevent serious complications. The study includes military personnel and affiliated civilians of any age who are not breastfeeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tecovirimat (oral tablet)
What this could lead to: If effective, tecovirimat could provide a treatment option for people exposed to dangerous orthopox viruses like smallpox or monkeypox, potentially reducing illness severity and spread.
What could go wrong: This is an early-stage protocol with limited data on efficacy in humans. The drug may not work as well in real-world outbreaks, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human infection by orthopoxvirus monkeypox smallpox vaccinia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MONKEYPOX SMALLPOX

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.